Tregalizumab, also known as BT-061, is a humanized mAb against the CD4 receptor. It works specifically on the immunoglobulin G (IgG)-like C2 type 1 domain of the CD4 receptor in Treg cells, inducing downstream phosphorylation events, leading to the activation of this important regulatory cell. The activation of Treg cells thus reduces the damaging effects of cytokines and T effector cells in active RA.

1. Hexa Reports
Market Research Reports and Insightful Company Profiles
Tregalizumab (Rheumatoid Arthritis) Global Share and Size,
Growth and Overview, Forecast and Market Analysis to 2023
Summary
Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of
the joints . It affects over seven million individuals in the 10MM covered in this report (US, France,
Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to
just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and
symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly
changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK
inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as
extremely effective therapies for RA, the market is extremely competitive for new entrants and will
undergo further pressure as biosimilars are approved and launch.
Tregalizumab, also known as BT-061, is a humanized mAb against the CD4 receptor. It works specifically
on the immunoglobulin G (IgG)-like C2 type 1 domain of the CD4 receptor in Treg cells, inducing
downstream phosphorylation events, leading to the activation of this important regulatory cell. The
activation of Treg cells thus reduces the damaging effects of cytokines and T effector cells in active RA.

2. Hexa Reports
Market Research Reports and Insightful Company Profiles
Browse Detail Report With TOC @ http://www.hexareports.com/report/tregalizumab-rheumatoid-
arthritis-forecast-and-market-analysis-to-2023/details
Scope
Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology
and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on Tregalizumab including product description, safety and efficacy profiles as well
as a SWOT analysis.
Sales forecast for Tregalizumab for the top 6 countries from 2013 to 2023.
Sales information covered for the US, France, Germany, Italy, Spain and the UK.
Reasons To Buy
Understand and capitalize by identifying products that are most likely to ensure a robust return.
Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid
Arthritis.
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales
potential.
Make more informed business decisions from insightful and in-depth analysis of Tregalizumab
performance.
Obtain sales forecast for Tregalizumab from 2013-2023 in top 6 countries (the US, France, Germany,
Italy, Spain and the UK).
Table Of Content
Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 9
Request A Sample copy of This Report @ http://www.hexareports.com/sample/42269
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 11
2.3 Upcoming Related Reports 14
3 Disease Overview 15
3.1 Etiology and Pathophysiology 15
3.1.1 Etiology 15
3.1.2 Pathophysiology 15
3.2 Symptoms 20
3.3 Prognosis 21

3. Hexa Reports
Market Research Reports and Insightful Company Profiles
3.4 Quality of Life 21
4 Disease Management 22
4.1 Diagnosis and Treatment Overview 22
4.1.1 Diagnosis 22
4.1.2 Treatment Guidelines 24
4.1.3 Leading Prescribed Drugs for the Treatment of RA 34
4.1.4 Clinical Practice 35
5 Competitive Assessment 41
5.1 Overview 41
6 Unmet Need and Opportunity 43
6.1 Overview 43
6.2 Development of Cost-Effective Therapies 44
6.2.1 Unmet Need 44
6.2.2 Gap Analysis 45
6.2.3 Opportunity 45
6.3 Biomarkers to Predict Responsiveness to Therapy 46
6.3.1 Unmet Need 46
Browse Full Report @ http://www.hexareports.com/report/tregalizumab-rheumatoid-arthritis-forecast-
and-market-analysis-to-2023/details
About Us:
Hexa Reports is a market research and consulting organization, offering industry reports, custom
research and consulting services to a host of key industries across the globe. We offer comprehensive
business intelligence in the form of industry reports which help our clients obtain clarity about their
business environment and enable them to undertake strategic growth initiatives.
Contact Information:
Ryan Shaw
Felton Office Plaza,
6265 Highway 9,
Felton, California, 95018,
United States
Phone Number
1-800-489-3075
Email Us: sales@hexareports.com
Our Website: http://www.hexareports.com/